This independent educational activity was supported by GSK.​ All content was developed independently by the faculty; the funder is allowed no influence on the content.

During the European School of Haematalogy (ESH) 4th How to Diagnose and Treat CML/MPN conference, the MPN Hub held a symposium on March 9, 2025, titled Anemia in myelofibrosis: Sequencing therapies to optimize patient outcomes. Here, we share a presentation by Francesco Passamonti, Università degli Studi di Milano, Milan, IT, discussing the treatment landscape for patients with myelofibrosis and anemia.

Firstly, Passamonti provided an overview of current treatment strategies for patients with myelofibrosis-related anemia, including red blood cell transfusion, erythropoiesis-stimulating agents, androgens, splenectomy, immunomodulatory drug agents, and Janus kinase inhibitors. He then discussed key efficacy and safety data from phase III trials of ruxolitinib, fedratinib, pacritinib, and momelotinib, with a focus on anemia.

Hosted on Acast. See acast.com/privacy for more information.